Status:
COMPLETED
A Survey to Evaluate Early Experience From Patient and Care Partner on Injection and Device for KESIMPTA® Indicated for Multiple Sclerosis
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18-100 years
Brief Summary
This was a US-based, observational cross-sectional study with primary data collection via questionnaires directly administered to patients with MS receiving KESIMPTA and care partners of patients with...
Detailed Description
The study aimed to enroll ninety-four (94) patients/care partners. The time period for enrollment was dependent on the uptake of KESIMPTA in the real-world. Data collected for the study was obtained ...
Eligibility Criteria
Inclusion
- Patients with MS
- Adult aged eighteen (18) years of age or over at the time of the survey
- Prescribed KESIMPTA within the prior 12 months and currently self-administering treatment using the Sensoready® pen
- MS diagnosis based on 2017 McDonald criteria
- Care Partner
- Adult aged eighteen (18) years of age or over
- Formal or informal care partner of patient with MS prescribed KESIMPTA within the prior 12 months
- Is currently administering KESIMPTA using the Sensoready® pen on their patient's behalf
- Patients with MS
Exclusion
- Previously used injection as a part of inclusion in any ofatumumab (OMB) randomized clinical trial
- Active Hepatitis B virus (HBV)
- Cognitive impairment that would impact their ability to participate in a survey study
Key Trial Info
Start Date :
November 24 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 15 2023
Estimated Enrollment :
105 Patients enrolled
Trial Details
Trial ID
NCT05334472
Start Date
November 24 2021
End Date
February 15 2023
Last Update
March 25 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
East Hanover, New Jersey, United States, 07936